VERICEL CORPORATION Retained Earnings
VERICEL CORPORATION (VCEL) had Retained Earnings of -$380.39 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-07-30
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$380.39M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$382.60M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$376.30M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$399.54M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$380.39M 10-Q · filed 2026-07-30 |
| 2026-03-31 | -$382.60M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$376.30M 10-Q · filed 2026-07-30 |
| 2025-09-30 | -$399.54M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$404.61M 10-Q · filed 2025-07-31 |
| 2025-03-31 | -$404.06M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$392.81M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$412.62M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$411.72M 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$407.04M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$403.18M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$416.17M 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$412.51M 10-Q · filed 2023-08-02 |
| 2023-03-31 | -$407.49M 10-Q · filed 2023-05-10 |
| 2022-12-31 | -$400.00M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$405.92M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$399.34M 10-Q · filed 2022-08-03 |
| 2022-03-31 | -$390.38M 10-Q · filed 2022-05-04 |
| 2021-12-31 | -$383.29M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$387.82M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$382.89M 10-Q · filed 2021-08-04 |
| 2021-03-31 | -$379.10M 10-Q · filed 2021-05-05 |
| 2020-12-31 | -$375.81M 10-K · filed 2022-02-24 |
| 2020-09-30 | -$388.04M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$391.65M 10-Q · filed 2020-08-05 |
| 2020-03-31 | -$383.38M 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$378.68M 10-K · filed 2021-02-24 |
| 2019-09-30 | -$388.18M 10-Q · filed 2019-11-05 |
| 2019-06-30 | -$391.65M 10-Q · filed 2019-08-06 |
| 2019-03-31 | -$371.86M 10-Q · filed 2019-05-07 |
| 2018-12-31 | -$369.01M 10-K · filed 2020-02-25 |
| 2018-09-30 | -$374.26M 10-Q · filed 2018-11-06 |
| 2018-06-30 | -$373.19M 10-Q · filed 2018-08-06 |
| 2018-03-31 | -$368.54M 10-Q · filed 2018-05-08 |
| 2017-12-31 | -$360.88M 10-K · filed 2019-02-26 |
| 2017-09-30 | -$361.16M 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$355.76M 10-Q · filed 2017-08-09 |
| 2017-03-31 | -$353.37M 10-Q · filed 2017-05-10 |
| 2016-12-31 | -$343.59M 10-K · filed 2018-03-05 |
| 2016-09-30 | -$337.39M 10-Q · filed 2016-11-07 |
| 2016-06-30 | -$330.72M 10-Q · filed 2016-08-08 |
| 2016-03-31 | -$327.68M 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$324.02M 10-K · filed 2017-03-13 |
| 2014-03-31 | -$293.76M 10-Q · filed 2014-05-15 |
| 2013-12-31 | -$287.76M 10-Q · filed 2014-05-15 |
| 2013-09-30 | -$284.80M 10-Q · filed 2013-11-12 |
| 2013-06-30 | -$287.01M 10-Q · filed 2013-08-07 |
| 2013-03-31 | -$282.12M 10-Q · filed 2013-05-08 |
| 2012-12-31 | -$275.31M 10-K · filed 2014-03-13 |
| 2012-09-30 | -$267.41M 10-Q · filed 2012-11-08 |
| 2012-06-30 | -$260.16M 10-Q · filed 2012-08-07 |
| 2012-03-31 | -$251.59M 10-Q · filed 2012-05-10 |
| 2011-12-31 | -$241.85M 10-K · filed 2013-03-18 |
| 2011-09-30 | -$239.06M 10-Q · filed 2011-11-08 |
| 2011-06-30 | -$237.13M 10-Q · filed 2011-08-15 |
| 2010-12-31 | -$222.18M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |